According to current guidelines, PD-L1 expression ≥50% was present in tumor samples from the 24 patients treated with pembrolizumab in monotherapy, while six patients treated with pembrolizumab plus chemotherapy presented PD-L1 expression lower than 1%. The gene discussed is CD274; the disease is neoplasm.